GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)

3 Months Ended

Jan. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

The following table presents goodwill balances and the movements for each of our reportable segments during the three months ended January 31, 2023:


	Life Sciences and Applied Markets		Diagnostics and Genomics		Agilent CrossLab		Total
	(in millions)
Goodwill as of October 31, 2022	$	1,743	$	1,953	$	256	$	3,952
Foreign currency translation impact	12		1		7		20
Goodwill arising from acquisitions and adjustments	—		11		—		11
Goodwill as of January 31, 2023	$	1,755	$	1,965	$	263	$	3,983

The component parts of other intangible assets as of January 31, 2023 and October 31, 2022 are shown in the table below:


	Other Intangible Assets
	Gross Carrying Amount		Accumulated Amortization		Net Book Value
	(in millions)
As of October 31, 2022
Purchased technology	$	1,733	$	1,068	$	665
Trademark/Tradename	196		148		48
Customer relationships	180		105		75
Backlog	8		8		—
Third-party technology and licenses	32		9		23
Total amortizable intangible assets	2,149		1,338		811
In-Process R&D	10		—		10
Total	$	2,159	$	1,338	$	821
As of January 31, 2023
Purchased technology	$	1,761	$	1,096	$	665
Trademark/Tradename	196		152		44
Customer relationships	181		113		68
Backlog	8		8		—
Third-party technology and licenses	33		10		23
Total amortizable intangible assets	2,179		1,379		800
In-Process R&D	10		—		10
Total	$	2,189	$	1,379	$	810

During the three months ended January 31, 2023, we recorded additions to goodwill of $11 million and to other intangible assets of $23 million in our diagnostics and genomics segment related to the acquisition of one business. During the three months ended January 31, 2023, other intangible assets in total increased $2 million due to the impact of foreign currency translation.

In general, for U.S. federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible.

Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. During the three months ended January 31, 2023 and 2022 we did not identify any triggering events or circumstances which would indicate an impairment of goodwill or indefinite-lived intangible assets.

Amortization expense of intangible assets was $36 million and $51 million for the three months ended January 31, 2023 and 2022, respectively.

Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2023 and for each of the next five fiscal years and thereafter is estimated below:


Estimated future amortization expense:
(in millions)
Remainder of 2023	$	109
2024	$	129
2025	$	104
2026	$	75
2027	$	73
2028	$	67
Thereafter	$	243